The UK and US have agreed to a major bilateral deal that will keep zero duties on British pharmaceutical products entering the American market.
Key Provisions of the Pact
Under the terms of the agreement, the UK has agreed to boost expenditure on drugs through the public health system. This move secures that tariffs on these crucial products will stay at nothing for a period of three years.
This agreement is in response to recent statements to dramatically increase duties on patented pharmaceutical products, with figures mentioned reaching double the cost.
"This arrangement with the United Kingdom bolsters the global environment for innovative medicines and establishes long-overdue balance to U.S.–U.K. drug exports," a release noted.
Commercial Impact
Pharmaceuticals constitute one of the Britain's largest exports to the US, which is by far the primary destination for large British pharmaceutical firms.
Statistics indicate that in the 12 months to the end of the third quarter, the UK exported drugs totaling billions to the US. This figure accounted for 17.4% of British export trade in that timeframe.
"This deal protects jobs, stimulates funding and paves the way for the UK to establish itself as a global hub for life sciences," the Business and Trade Secretary remarked.
Key British Pledges
The deal includes several specific changes from the United Kingdom:
- Revised Affordability Limit: The UK will raise the price threshold at which it judges new therapies to be unaffordable by twenty-five percent.
- Higher Drug Budget: There is a aim to increase overall public funding on medicines from 0.3% of GDP to 0.6% over the coming ten years.
- Rebate Cap: The sum manufacturers must refund to the NHS to prevent overspending will be limited at 15%. In the past, rebates were more than twenty percent.
Recent Tensions
This agreement follows a long-running row between the pharmaceutical industry and the British authorities over spending levels and NHS adoption.
This friction were heightened by claims that US customers were paying several times more for the same drugs than people in the UK and Europe.
Recently, several major drug company projects in the UK have been paused or scrapped, while multi-billion-dollar expansions have been announced toward American operations.
One official stated that the NHS must invest a greater share on medicines, noting that its expenditure on drugs had declined as a share of its resources over the last ten years.
